Generic Lidex Ointment by Lupin receives FDA approval

August 03, 2017 | Thursday | News

Lidex Ointment had US sales of USD 40.3 million

Source: Pixabay

Source: Pixabay

Pharma company Lupin Limited has announced that United States Food and Drug Administration (USFDA) has finally approved its Fluocinonide Topical Ointment USP, 0.05% to market a generic version of County Line Pharmaceuticals, LLC’s Lidex Ointment, 0.05%.

Indicated for the relief of the inflammatory and pruritic manifestations of corticosteroid-responsive dermatoses, Lupin’s Fluocinonide Topical Ointment USP, 0.05% is AB rated generic equivalent of LLC’s Lidex Ointment, 0.05%.

Lidex Ointment had US sales of USD 40.3 million (IMS MAT March 2017).

Comments

× Your session has expired. Please click here to Sign-in or Sign-up

Have an Account?

Forgot your password?

First Name should not be empty!

Last Name should not be empty!

Email address should not be empty!

Show Password should not be empty!

Show Confirm Password should not be empty!

Newsletter

E-magazine

Biospectrum Infomercial

Bio Resource

I accept the terms & conditions & Privacy policy